Raised a total of 4.0 billion yen through a third-party allotment of 3.0 billion yen for new shares and 1.0 billion yen for unsecured bonds. The allottee is JICVGI Opportunity Fund No. 1. The funds will be allocated to research and development for second-generation cardiomyocyte sheets, catheter treatments, in vivo regenerative factor inducers, and mesenchymal stem cell research, etc. To limit dilution, a mix of equity and debt was used to accelerate growth strategy including overseas expansion of ReHeart. After listing, concrete plans for fund usage and stability of the allottee are explained.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4894","jir_company_name":"Qualips Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4894-20260911-02.pdf","jir_short_summary":"Raised a total of 4.0 billion yen through a third-party allotment of 3.0 billion yen for new shares and 1.0 billion yen for unsecured bonds. The allottee is JICVGI Opportunity Fund No. 1. The funds will be allocated to research and development for second-generation cardiomyocyte sheets, catheter treatments, in vivo regenerative factor inducers, and mesenchymal stem cell research, etc. To limit dilution, a mix of equity and debt was used to accelerate growth strategy including overseas expansion of ReHeart. After listing, concrete plans for fund usage and stability of the allottee are explained.","jir_summary":"### Overview of the financing\nThis supplementary explanatory document specifies a total funding of 4.0 billion yen raised through the issuance of new shares via a third-party allotment and the issuance of the first unsecured ordinary bonds with the same sponsor. The allottee is JICVGI Opportunity Fund No. 1 Investment Limited Partnership, with an issuance amount of 3.0 billion yen in new shares and 1.0 billion yen in bonds, designed to minimize dilution. The use of funds is disclosed as accelerating R&D for the second-generation cardiomyocyte sheet and expanding ReHeart-related businesses.\n\n### Relation between business strategy and capital policy\nThe purpose of the financing is to expand growth drivers after ReHeart's domestic approval and to strengthen R&D across the pipeline including overseas expansion. Specifically, plans to accelerate development in the areas of the second-generation cardiomyocyte sheets, catheter treatments, in vivo regenerative factor inducers, and MSCs. The allottee is an investment partnership backed by a government-related fund, expected to provide long-term growth support.","jir_financial_highlights":"Total funds raised in this financing: 4 \u5104\u5186 (\u4e0d\u660e)\nAmount of new share issuance: 3 \u5104\u5186 (\u4e0d\u660e)\nAmount of first unsecured bond issuance: 1 \u5104\u5186 (\u4e0d\u660e)","jir_category":"","jir_hashtags":"#Qualips Co., Ltd., #capital_policy, #new_share_issuance, #bond_issuance","jir_key_figures":"Total funds raised in this financing: 4 \u5104\u5186\nAmount of new share issuance: 3 \u5104\u5186\nAmount of first unsecured bond issuance: 1 \u5104\u5186","jir_meta_title":"\u3010Qualips Co., Ltd.\u3011Capital Policy: Announcement of 4.0 billion yen through Third-Party Allotment and Bond Issuance | September 2026","jir_meta_description":"Qualips conducts a funding round totaling 4.0 billion yen via third-party allotment of 3.0 billion yen in new shares and 1.0 billion yen in unsecured bonds. Allottee is JICVGI. Funds allocated to R&D for the second-generation cardiomyocyte sheets, accelerating a growth strategy aimed at international expansion.","jir_og_title":"Qualips Announces 4 Billion Yen Financing \u2014 Accelerating Growth Strategy","jir_og_description":"Funds raised through third-party allotment and bond issuance total 4 billion yen. Allottee is JICVGI. Accelerating R&D in ReHeart-related fields and pursuing a growth strategy with overseas expansion in view.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17194,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-113187","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n